logo
Plus   Neg
Share
Email

Cincinnati Financial Profit Falls Amid Revenue Growth, Misses Estimate

Property and casualty insurer Cincinnati Financial Corp (CINF) Thursday reported first-quarter net earnings of $91 million or $0.55 per share compared with $151 million or $0.94 per share last year.

Excluding items, operating earnings for the quarter were $77 million or $0.46 per share compared with $128 million or $0.78 per share a year ago.

Analysts polled by Thomson Reuters estimated earnings of $0.55 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter were up 8% at $1.19 billion compared with $1.1 billion in the prior year. Analysts estimated revenues of $1.16 billion for the quarter.

Total benefits and expenses for the quarter escalated to $1.07 billion from $886 million in the prior year.

Property casualty combined ratio for the quarter worsened to 100.3 percent from 91.2 percent last year.

At the end of the quarter, the company had a book value of $37.73 per share, compared with $35.41 per share a year ago.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT